scholarly journals Serum Secretogranin III Concentrations Were Increased in Subjects with Metabolic Syndrome and Independently Associated with Fasting Plasma Glucose Levels

2019 ◽  
Vol 8 (9) ◽  
pp. 1436 ◽  
Author(s):  
Chun-Chung Lin ◽  
Kai-Pi Cheng ◽  
Hao-Chang Hung ◽  
Chung-Hao Li ◽  
Ching-Han Lin ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Pancreatic Beta Cells ◽  
Secretory Granules ◽  
High Sensitivity ◽  
Metabolic Parameters ◽  
Glucose Levels ◽  
Fasting Plasma ◽  
High Fasting Plasma Glucose

Secretogranin III (SCG3) plays a crucial role in the biogenesis of secretory granules in endocrine cells, and thus affects glucose homeostasis by regulating insulin secretion by pancreatic beta cells. Insulin resistance and compensatory hyperinsulinemia are hallmarks of metabolic syndrome (MetS). However, the role of SCG3 in MetS remains unclear. Therefore, we investigated the relationship between serum SCG3 levels and metabolic parameters in subjects with and without MetS. This was a case control study, and 295 subjects were recruited. Serum SCG3 concentrations were compared between groups. Associations between SCG3 levels and clinico-metabolic parameters were also examined. We found serum SCG3 levels were higher in the MetS group than non-MetS group (122.6 ± 79.2 vs. 90.6 ± 58.5 nmol/L, p = 0.009). Specifically, elevated SCG3 levels were found in subjects with high fasting plasma glucose (FPG) levels, central obesity, or hypertriglyceridemia. Additionally, MetS was an independent factor of serum SCG3 levels in multivariate linear regression analyses. Moreover, FPG, free fatty acids, and waist circumference were positively associated with serum SCG3 concentrations after adjusting for insulin levels, high-sensitivity C-reactive protein, and cardiovascular risk factors. In conclusion, serum SCG3 concentrations were higher in subjects with MetS and were independently associated with FPG levels.

scholarly journals Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome—A Systematic Review

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2291 ◽  
Author(s):  
Zhang ◽  
Mocanu ◽  
Cai ◽  
Dang ◽  
Slater ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Body Mass Index ◽  
Insulin Sensitivity ◽  
Body Mass ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Fecal Microbiota Transplantation ◽  
Fecal Microbiota ◽  
Metabolic Parameters ◽  
Fasting Plasma

Fecal microbiota transplantation (FMT) is a gut microbial-modulation strategy that has been investigated for the treatment of a variety of human diseases, including obesity-associated metabolic disorders. This study appraises current literature and provides an overview of the effectiveness and limitations of FMT as a potential therapeutic strategy for obesity and metabolic syndrome (MS). Five electronic databases and two gray literature sources were searched up to 10 December 2018. All interventional and observational studies that contained information on the relevant population (adult patients with obesity and MS), intervention (receiving allogeneic FMT) and outcomes (metabolic parameters) were eligible. From 1096 unique citations, three randomized placebo-controlled studies (76 patients with obesity and MS, body mass index = 34.8 ± 4.1 kg/m2, fasting plasma glucose = 5.8 ± 0.7 mmol/L) were included for review. Studies reported mixed results with regards to improvement in metabolic parameters. Two studies reported improved peripheral insulin sensitivity (rate of glucose disappearance, RD) at 6 weeks in patients receiving donor FMT versus patients receiving the placebo control. In addition, one study observed lower HbA1c levels in FMT patients at 6 weeks. No differences in fasting plasma glucose, hepatic insulin sensitivity, body mass index (BMI), or cholesterol markers were observed between two groups across all included studies. While promising, the influence of FMT on long-term clinical endpoints needs to be further explored. Future studies are also required to better understand the mechanisms through which changes in gut microbial ecology and engraftment of microbiota affect metabolic outcomes for patients with obesity and MS. In addition, further research is needed to better define the optimal fecal microbial preparation, dosing, and method of delivery.

scholarly journals Prevalence of Metabolic Syndrom in Three Urban Communities of Dhaka City

1970 ◽  
Vol 2 (2) ◽  
pp. 44-48 ◽  
Author(s):  
Shurovi Sayeed ◽  
Akhter Banu ◽  
Parvin Akter Khanam ◽  
Sharmina Alauddin ◽  
Sabrina Makbul ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Urban Communities ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Urban Population ◽  
Population Characteristics ◽  
Dhaka City ◽  
Fasting Plasma ◽  
Prevalence Of Obesity ◽  
The Mean

Bangladeshis are prone to develop type 2 diabetes mellitus (T2DM), hypertension (sHTN and dHTN) and atherosclerotic heart diseases, observed more predominantly in the urban population. Though metabolic syndrome (MetS) is a related disorder, there are few studies in this regard. The prevalence of obesity, T2DM and MetS in three urban communities of Bangladesh were addressed in this study. Nine hundred non-slum urban households in three Dhaka City Wards were randomly selected. One member (age ≥ 25y) from each household was invited for investigation with an overnight fast. Socio-demographic information as well as height, weight, waist-girth, hip-girth and blood pressure were measured. Fasting plasma glucose (FPG), total cholesterol (chol), triglycerides (TG) and high-density lipoproteins-c (HDL) were estimated. A total of 705 (m / f = 239 / 466) subjects volunteered for the study. The mean value with 95% confidence interval (CI) of age was 42.4 (40.9 - 43.1) years for men and 37.8 (36.8 - 38.7) for women. The mean (CI) body mass index (BMI) was 21.0 (20.6 - 21.5) and 22.6 (22.2 - 22.9) and waist hip ratio (WHR) was 0.84 (0.83 - 0.84) and 0.82 (0.81 - 0.83), respectively for men and women. The mean (CI) FPG (fasting plasma glucose) was 5.5 (5.2 - 5.7) for men and 5.2 (5.0 - 5.4) for women. The prevalence of obesity (BMI ≥ 25.0) was 21%, T2DM (FPG ≥ 6.1 mmol/l) was 22.2%, triglyceridemia (TG ≥ 150mg/dl) was 45.1% and low HDL-c (HDL<40mg/ dl) was 43.8%. The crude prevalence of MetS varied based on different cluster combinations, being the lowest (0.3%) recommended by WHO cluster (FPG + BMI + SBP/DBP) and the highest (8.7%) by International Diabetes Federation (IDF) cluster (waist + FPG + HDL). The MetS was found higher in male than female by NCEP criteria and higher in female than male by IDF criteria. The study revealed an increased prevalence of obesity, T2DM and MetS in the urban communities. It also revealed that T2DM and MetS are moderately common and of growing healthcare burden in the rapidly growing urban population. Additionally, the study observed the wide ranging prevalence rates of MetS in the same study population indicating the need to establish a consistent and useful MetS-cluster depending on population characteristics. Ibrahim Med. Coll. J. 2008; 2(2): 44-48 Key Words: Metabolic syndrome, urban, diabetes, hypertension, dyslipidemia   doi: 10.3329/imcj.v2i2.2936

scholarly journals The associations between fasting plasma glucose levels and mortality of COVID-19 in patients without diabetes

2020 ◽  
Vol 169 ◽  
pp. 108448
Author(s):  
Yun Huang ◽  
Heming Guo ◽  
Yan Zhou ◽  
Jingjing Guo ◽  
Tiantian Wang ◽  
...  
Keyword(s):  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Glucose Levels ◽  
Fasting Plasma

scholarly journals The Global, Regional, and National Burden and Trends of Breast Cancer From 1990 to 2019: Results From the Global Burden of Disease Study 2019

2021 ◽  
Vol 11 ◽  
Author(s):  
Shangbo Xu ◽  
Yiyuan Liu ◽  
Taofeng Zhang ◽  
Jiehua Zheng ◽  
Weixun Lin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Plasma Glucose ◽  
Fasting Plasma Glucose ◽  
Burden Of Disease ◽  
Global Burden Of Disease ◽  
Global Burden ◽  
Fasting Plasma ◽  
Life Years ◽  
High Fasting Plasma Glucose

BackgroundThe burden of breast cancer has been increasing globally. The epidemiology burden and trends need to be updated. This study aimed to update the burden and trends of breast cancer incidences, deaths, and disability-adjusted life-years (DALYs) from 1990 to 2019, using the Global Burden of Disease 2019 study.MethodsThe data of incidences, deaths, DALYs, and age-standardized rates were extracted. Estimated annual percentage changes were used to quantify the trends of age-standardized rates. Besides, the population attributable fractions of the risk factors of breast cancer were also estimated.ResultsGlobally, the incidences of breast cancer increased to 2,002,354 in 2019. High social-development index (SDI) quintiles had the highest incidence cases with a declining trend in age-standardized incidence rate. In 2019, the global deaths and DALYs of breast cancer increased to 700,660 and 20,625,313, respectively. From 1990 to 2019, the age-standardized mortality rates and age-standardized DALY rates declined globally, especially in high and high-middle SDI quintiles. Besides, the trends varied from different regions and countries. The proportion of the patients in the 70+ years age group increased globally. Deaths of breast cancer attributable to high fasting plasma glucose and high body mass index increased globally, and high fasting plasma glucose was the greatest contributor to the global breast cancer deaths.ConclusionThe burden of breast cancer in higher SDI quintiles had gone down while the burden was still on the rise in lower SDI quintiles. It is necessary to appeal to the public to decrease the exposure of the risk factors.

Sign in / Sign up

Export Citation Format

Share Document